Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus.

Burcin Cansu Bozca Asli Bilgic Temel Soner Uzun

Published in: The Journal of dermatological treatment (2021)

Additional rituximab cycles may help achieve and prolong remission in patients with moderate-to-severe pemphigus resistant to conventional therapies. However, prospective trials are needed to identify the optimal dosing protocol.

Keyphrases

diffuse large b cell lymphoma
high intensity
early onset
randomized controlled trial
chronic lymphocytic leukemia
hodgkin lymphoma
drug induced
disease activity
rheumatoid arthritis